The recent development of viral vectors, especially vectors derived from adeno-associated virus (AAV), has translated gene therapy for Parkinson's disease (PD) from animal experiments into clinical trials. The current gene therapy protocols used are based on three major strategies. The first protocol involves local production of dopamine via the introduction of dopamine-synthesizing enzyme genes into the putamen. The aromatic L-amino acid decarboxylase (AADC) gene has been transferred in this manner with the aim of efficiently converting orally administered L-dopa. The delivery of triple genes including tyrosine hydroxylase (TH), guanosine triphosphate cyclohydrolase I (GCH) and AADC is also being undertaken, and is aimed at continuously supplying dopamine into the putamen. The second protocol involves the protection of nigrostriatal projections via the production of neurturin, a trophic factor for dopaminergic neurons in the putamen. The final method includes the modulation of neural activity along the output pathway of the basal ganglia by transducing the subthalamic nucleus with vectors expressing glutamic acid decarboxylase (GAD-65, GAD-67), a key enzyme required for the synthesis of the inhibitory transmitter γ-aminobutyric acid (GABA). The initial results of phase 1 studies using AAV vectors have not only confirmed the safety of these vectors, but have also revealed the alleviation of motor symptoms associated with PD.
Introduction
(SIRS) following the administration of a large quantity of 1 adenoviral vector into the hepatic artery. In addition, some Almost two decades have passed since the first gene therapy children with X-linked severe combined immunodeficiency (Xclinical trial was conducted for the treatment of adenosine SCID) developed leukemia due to the activation of an oncogene deaminase deficiency at the National Institute of Health in the 2, 3 after gene therapy using a retroviral vector. These reports United States in 1990. Although gene therapy appeared to be a describing the severe, adverse effects of gene therapy dampened ground breaking form of medical treatment at the time, it has the excitement underlying the success of gene therapy treatment not proven to be as successful in treating disease as initially to some extent. However, encouraging results have been obtained anticipated. A patient with ornithine transcarbamylase [4] [5] [6] [7] deficiency died of systemic inflammatory response syndrome more recently with clinical studies for Parkinson's disease (PD). GPe, globus pallidus external segment; genetic tool in the neurosciences. function in the off-state improved to a GPi, globus pallidus internal segment; mean of 46% (11.6 points) based on the G e n e t r a n s f e r o f d o p a m i n e -TH, tyrosine hydroxylase; SNc, substantia UPDRS scores at six months after surgery, synthesizing enzymes nigra pars compacta; STN, subthalamic without any apparent changes in the Dopamine is synthesized in the brain nucleus.
short-duration response to levodopa. PET from diet-derived L-tyrosine. Three Adeno-associated virus vectors revealed a 56% increase in FMT activity, enzymes are essential in this production which persisted for up to 96 weeks 19 Technology that efficiently introduces a process. Tyrosine hydroxylase (TH) is the (manuscript in preparation). Phase 2 therapeutic gene into target cells is rate-limiting enzyme that converts Ltrials of AAV-AADC are currently in the essential for successful gene therapy.
tyrosine to L-3, 4-dihydroxy-phenylaplanning stages. Viral vectors, in particular vectors derived lanine (L-dopa). Guanosine triphosphate from adeno-associated virus (AAV), have Using a vector derived from the equine cyclohydrolase I (GCH) is the rate-limiting been shown to be suitable for the infectious anemia virus (EIAV), a type of enzyme that synthesizes the essential TH transduction of neurons in the co-factor tetrahydrobiopterine (BH ), lentivirus, a phase I/II trial involving the 4 mammalian brain using stereotaxic triple gene transfer of TH, GCH and AADC while aromatic L-amino acid decarboxy-8 surgery. AAVs are small (25 nm), single into the bilateral putamen has been lase (AADC) converts L-dopa to stranded DNA viruses that belong to initiated at the Henri Mondor Hospital in dopamine. These three enzymes are 9 22 Parvoviridae. No clear pathogenicity in France. Two dose levels have been transported from the substantia nigra in humans has been reported, and many evaluated in cohorts of three patients per an anterograde manner to the striatum. adults synthesize antibodies against dose. All patients treated at the second A severe loss of the nerve terminals in AAVs following latent infection in dose level have completed their sixadvanced Parkinson's disease (PD) is 10, 11 childhood.
The AAV genome exists in associated with an 80-95% depletion of month assessments and have shown episomes in the nucleus and is rarely striatal enzyme activity. (GDNF). GDNF is a small glycoprotein the STN to the internal portion of the been tested in clinical trials, with the that provides strong trophic support for globus pallidus (GPi) and to the initial results of phase I studies proving the dopaminergic neurons. However, substantia nigra pars reticulata (SNr) encouraging. In contrast to cell GDNF protein has limited usefulness as a then exerts inhibitory effects on the transplantation, immunosuppressive therapeutic agent due to its short t h a l a m o -c o r t i c a l p r o j e c t i o n a n d drugs are not necessary for the current duration of activity and poor ability to brainstem nucleus, resulting in motor gene therapy strategies. If the primary cross the blood-brain barrier. In animal symptoms such as bradykinesia and purpose of treatment is the supplemodels of neurotoxin induced PD, viral rigidity. During the last two decades, mentation of dopamine into the striatum vector-mediated gene delivery halts deep brain stimulation of the STN, which for improving motor performance, then o n g o i n g d e g e n e r a t i o n o f t h e is thought to modify STN output by highgene therapy appears to be simpler than nigrostriatal pathway, resulting in frequency stimulation, has become cell transplants. Cell therapy may prove f u n c t i o n a l r e c o v e r y, e v e n a f t e r routine treatment for advanced PD useful in treating Parkinsonism including substantial numbers of dopaminergic patients and has resulted in the cerebral ischemia, striato-nigral 24, 25 cells have been depleted. improvement of motor function. Gene d e g e n e r a t i o n a n d c o r t i c o -b a s a l transfer of glutamic acid decarboxylase degeneration, where neurons in the A phase I gene therapy trial that (GAD-65 and GAD-67), a rate-limiting striatum are damaged. However, several introduced the neurturin gene into the enzyme required for the synthesis of PD symptoms that L-dopa is not effective bilateral putamen was conducted at the 6 inhibitory transmitter γ-aminobutyric a t res cu i n g i nc l u di n g c o gn i t i v e UCSF . The first six patients entered into 11 acid (GABA), into the STN is aimed at dysfunction, depressive state, frozen the study receiving a dose of 310 vg, converting excitatory output to inhibitory gait, posture reflex disturbance and sleep while the next six patients received a dose 32 11 output, thus, obtaining a similar effect to disturbance have also been reported. of 5.410 vg of AAV vector. A mean 28 electrical stimulation.
For the treatment of these symptoms, improvement of 36% (14 points) in the effective therapeutic genes must be An open-label phase I clinical trial has UPDRS motor score in the off-state and a identified and delivered into the been conducted at the New York mean increase of 25% (2.3 h) in on time 5 appropriate areas of the brain. Presbyterian Hospital. A total of 12 without troublesome dyskinesia were Development of vector constructs that patients in three dose-escalation cohorts observed one year after surgery.
avoid over-expression is also required for received AAV-GAD into the unilateral STN Subsequently, a phase II double-blind 33 increasing safety. Although AAV and contra-lateral to more severe motor control study was undertaken at nine EIAV are reported to be non-pathogenic symptoms. At 12 months after the vector academic institutions in the United for humans, the long-term safety must be infusion, the mean improvement on States, and in which one-third of a total confirmed. It is expected that in the near motor score of UPDRS was 27% in the offof 54 patients received sham surgery 5 future gene therapy will become the (partial burr hole without infusion of state and 24% in the on-state. A PET scan 18 general choice for the treatment of PD. vectors). Significant differences were not using [ F]fluorodeoxyglucose (FDG) as a obtained in terms of the degree of motor tracer revealed a decrease in uptake into performance between the gene transfer the ventrolateral nucleus (VL) and group and the control group at 12 dorsomedial nucleus (MD) of the months, although some treatment thalamus on the operated side, and an References effects have since been observed in 30 increased uptake in the ipsilateral 29 subjects followed for 18 months under premotor and motor cortical regions. ANNALS OF NEUROSCIENCES VOLUME 17 NUMBER 2 APRIL 2010 www.annalsofneurosciences.org
